Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of vericiguat in chronic heart failure with reduced ejection fraction
2020-005941-18Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Vericiguat arm with Placebo arm (2 arms). Primary endpoint: Time to first occurrence of composite endpoint of cardiovascular death or heart failure hospitalization. Started Aug 2021; status: active.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2020-005941-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005941-18.